Cart
sales@molnova.com
CFTR corrector 12
CAS No. 958941-60-1
CFTR corrector 12( —— )
Catalog No. M37242 CAS No. 958941-60-1
CFTR corrector 12 is a CFTR corrector that rescues all mutant proteins except M760R ABCA3, and can be used to study cystic fibrosis.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 432 | In Stock |
|
| 10MG | 613 | In Stock |
|
| 25MG | 938 | In Stock |
|
| 50MG | 1283 | In Stock |
|
| 100MG | 1739 | In Stock |
|
| 200MG | 2344 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCFTR corrector 12
-
NoteResearch use only, not for human use.
-
Brief DescriptionCFTR corrector 12 is a CFTR corrector that rescues all mutant proteins except M760R ABCA3, and can be used to study cystic fibrosis.
-
DescriptionCFTR corrector 12 (compound 17C) is a bithiazole derivative, serving as CFTR corrector. CFTR corrector 12 has the ability to correct some folding defective mutants of the channel responsible for the control of chloride transport across the plasma membrane. CFTR corrector 12 recovers the α-sarcoglycan (α-SG) content in mutant cells.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetCFTR
-
RecptorCFTR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number958941-60-1
-
Formula Weight436.98
-
Molecular FormulaC19H21ClN4O2S2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(NC1=NC(=C(S1)C=2N=C(SC2)NC3=CC(Cl)=CC=C3OC)C)C(C)(C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Ribaudo G, et al. Synthesis and Evaluation of Bithiazole Derivatives As Potential α-Sarcoglycan Correctors. ACS Med Chem Lett. 2023 Jul 28;14(8):1049-1053.
molnova catalog
related products
-
Nesolicaftor
PTI-428 specifically enhances cystic fibrosis transmembrane conductance regulator protein synthesis.
-
GLPG-2222
GLPG-2222 (ABBV-2222, Galicaftor)?is a novel potent and efficacious CFTR corrector with EC50 of 5 nM; is highly potent (5 nM) and efficacious in cells from multiple CF patient donors that have F508del homozygous mutation.
-
SRI-37240
SRI-37240 is a potent inhibitor of premature termination codons (PTCs) with read-across activity that induces a prolonged pause at the termination codon and inhibits PTCs associated with cystic fibrosis.
